Health Ministry Considers Deadline Extension for Pharma Firms to Meet Stricter GMP Standards

The updated Schedule M norms, designed to elevate manufacturing quality and align India’s pharmaceutical production with global benchmarks, introduce enhanced requirements for quality systems, documentation, risk management and upgraded infrastructure.

News

The Union Health Ministry is exploring the possibility of granting extra time to select pharmaceutical manufacturers to comply with the newly revised Good Manufacturing Practices (GMP) standards under Schedule M of the Drugs and Cosmetics Rules. The deliberations are underway with state governments and drug regulators, amid concerns over industry readiness.

The updated Schedule M norms, designed to elevate manufacturing quality and align India’s pharmaceutical production with global benchmarks, introduce enhanced requirements for quality systems, documentation, risk management and upgraded infrastructure. These standards are intended to strengthen patient safety and ensure the consistent production of high-quality medicines.

However, several small and medium-sized firms have voiced difficulties in meeting the compliance deadlines set for the new GMP regime. Industry representatives argue that stringent enforcement without flexibility could force many units to shut operations, disrupt the supply of essential medicines and impact employment within the sector.

Officials familiar with the talks say the ministry may offer conditional extensions to companies that have demonstrated tangible progress towards compliance. Any additional time granted would likely include strict monitoring and time-bound action plans to ensure that quality standards are upheld, not diluted.

Government sources emphasize that protecting public health and maintaining drug quality remains non-negotiable. The approach being considered aims to balance regulatory rigor with practical support for manufacturers striving to adapt to the elevated norms.

The potential extensions come at a crucial time for India’s pharmaceutical industry, which is among the world’s largest suppliers of generic medicines. Delays in compliance could have ripple effects across domestic and global supply chains if not managed with careful oversight.